Developing cause-oriented treatment for Parkinson's, Alzheimer's, and Lou Gehrig's diseases based on preventing mitochondrial DNA damage, the earliest recognized event in these neurodegenerative disorders, with proprietary polyamine drug, Tetramine.
Verne Mendel Medical Corporation
Verne Mendel Medical Corporation
2024-08-23
Business, Biotechnology and Pharmaceuticals, Pharmaceuticals, Research and Development - Verne Mendel Medical Corporation. Developing cause-oriented treatment for Parkinson's, Alzheimer's, and Lou Gehrig's diseases based on preventing mitochondrial DNA damage, the earliest recognized event in these neurodegenerative disorders, with proprietary polyamine drug, Tetramine.